Premium
AG‐4 complement‐fixing antibodies in cervical cancer and herpes‐infected patients using local herpes simplex virus type 2
Author(s) -
Arsenakis M.,
Georgiou G. M.,
Welsh J. K.,
Cauchi M. N.,
May J. T.
Publication year - 1980
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910250109
Subject(s) - herpes simplex virus , antibody , hsl and hsv , virology , carcinoma , cervical cancer , medicine , virus , cancer , biology , immunology , pathology
The incidence of anti‐AG‐4 complement‐fixing antibodies in Australian cervical carcinoma (CaCx), herpes simplex virus (HSV) type 1 and 2, and control patients, was investigated using local HSV strains. The local HSV strains (both HSV‐1Ml and HSV‐2Ml) were found, by neutralization experiments, to vary from the American prototype strains. All HSV‐2 strains tested were able to induce AG‐4 in 4‐h infected HEp‐2 cells. Anti‐AG‐4 complement‐fixing antibodies were detected in 40% of dysplasia patients, 60% of carcinoma‐in‐situ patients, 75% of CaCx patients, 65% of CaCx post‐operative patients, 88% of HSV‐2 patients with active lesions, 10% of HSV‐1 patients with active lesions, 10–20% of normal patients and 20% of patients with cancer, other than CaCx. The AG‐4 test is tumour‐specific in that it distinguishes CaCx from other cancer patients tested, but it cannot distinguish HSV‐2 patients from CaCx patients.